Breast cancer characteristics in very young Egyptian women ≤35 years

Figures & data

Table 1 Patients’ characteristics

Personal data	Item	N =300	%
Marital status	Single	43	14.3
	One child	73	24.3
	Two children	70	23.3
	Three children	114	38
Family history	No	263	87.7
	Mother	13	4.3
	Aunt	15	5
	Sister	4	1.3
	Mother and aunt	5	1.7
Pregnancy at presentation	Yes	13	4.3
	No	287	95.7

Abbreviation: No, number.

Table 2 Tumor pathologic characteristics

Tumor characteristics	Item	No=300	%
Side	Rt	158	52.7
	Lt	141	47
	Bilateral	1	0.3
T	1	46	15.3
	2	175	58.3
	3	40	13.3
	4	39	13
N	0	73	24.3
	1	81	27
	2	65	21.7
	3	81	27
M	0	286	95.3
	1	14	4.7
Pathology types	IDC	243	81
	ILC	39	13
	Medullary	10	3.3
	Other	8	2.7
Associated in situ components	No	246	82
	Yes	54	18
Grade	1	9	3
	2	199	66.3
	3	92	30.7
	Median	Mean (SD)	Range
Tumor size	3.0	3.9 (2.1)	0.6–12.0
LN positive	3	5 (6)	0–28
LN resected	13	14 (5)	8–32

Abbreviations: Rt, right; Lt, left; T, tumor; N, node; M, metastasis; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; SD, standard deviation; LN, lymph node; No, number.

Table 3 Tumor biomarker characteristics

Biomarkers	Item	No	%
ER	Negative	153	51
	Positive	147	49
PR	Negative	145	48.3
	Positive	155	51.7
Hormone receptors	Negative	124	41.3
	Positive	176	58.7
HER2 (217 cases)	Negative	135	62.2
	Positive	82	37.8
Subtypes (216 cases)	Luminal A-like	7	3.2
	Luminal B-like	107	49.5
	HER2 overexpression	45	20.8
	Triple-negative	57	26.4
	Median	Mean (SD)	Range
Ki 67 (%)	35	35 (21)	3–66

Abbreviations: ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation; No, number.

Table 4 Treatment options

Management	Item	No	%
Surgery (286 non-metastatic cases)	MRM	134	46.9
	Conservative mastectomies + immediate breast reconstruction	87	30.4
	NSM + LD	70	24.5
	SSM + LD	17	5.9
	BCS	65	22.7
Chemotherapy	Metastatic	14	4.7
	Neoadjuvant	132	44
	Adjuvant	154	51.3
Complete PCR after neoadjuvant therapy (132 cases)	No	111	84.1
	Yes	21	15.9
Radiotherapy	No	33	11
	Yes	267	89
Endocrine therapy	No	124	41.3
	Tamoxifen	126	42
	Tamoxifen + LHRH	50	16.7
Trastuzumab (82 positive cases)	No	2	2.4
	For 1 year	80	97.6

Abbreviations: MRM, modified radical mastectomy; NSM, nipple-sparing mastectomy; LD, latissimus dorsi; SSM, skin-sparing mastectomy; BCS, breast-conserving surgery; PCR, pathologic complete response; LHRH, leutenizing hormone-releasing hormone; No, number.

Figure 1 The median DFS was 61 months (95% confidence interval 44–78 months); the 3-year and 5-year DFS were 58% and 50%, respectively.

Abbreviation: DFS, disease-free survival.

Figure 2 The 3-year and 5-year OS were 88% and 68%, respectively.

Abbreviation: OS, overall survival.